GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » ROC %

Australian Clinical Labs (ASX:ACL) ROC % : 5.13% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Australian Clinical Labs's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 5.13%.

As of today (2024-06-06), Australian Clinical Labs's WACC % is 8.30%. Australian Clinical Labs's ROC % is 3.85% (calculated using TTM income statement data). Australian Clinical Labs earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Australian Clinical Labs ROC % Historical Data

The historical data trend for Australian Clinical Labs's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs ROC % Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23
ROC %
- 15.95 33.10 6.15

Australian Clinical Labs Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC % Get a 7-Day Free Trial 47.75 16.25 9.90 2.49 5.13

Australian Clinical Labs ROC % Calculation

Australian Clinical Labs's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=51.967 * ( 1 - 25.39% )/( (651.145 + 609.515)/ 2 )
=38.7725787/630.33
=6.15 %

where

Invested Capital(A: Jun. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=628.042 - 59.189 - ( 26.372 - max(0, 225.163 - 142.871+26.372))
=651.145

Invested Capital(A: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=578.913 - 41.364 - ( 19.955 - max(0, 187.925 - 115.959+19.955))
=609.515

Australian Clinical Labs's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=47.95 * ( 1 - 34.99% )/( (609.515 + 606.711)/ 2 )
=31.172295/608.113
=5.13 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=578.913 - 41.364 - ( 19.955 - max(0, 187.925 - 115.959+19.955))
=609.515

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=583.723 - 41.243 - ( 24.938 - max(0, 189.992 - 125.761+24.938))
=606.711

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Australian Clinical Labs  (ASX:ACL) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Australian Clinical Labs's WACC % is 8.30%. Australian Clinical Labs's ROC % is 3.85% (calculated using TTM income statement data). Australian Clinical Labs earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Australian Clinical Labs ROC % Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs (ASX:ACL) Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines